Sanhe Biotech, a Hong Kong-based biotechnology firm, is facing allegations of unpaid wages and reimbursements from former employees, according to a report by Hong Kong 01 published on April 5, 2024.
Several staff members have come forward claiming they were not paid in full for their work, with one employee stating they were owed over HK$1 million in back pay. Others said the company had failed to reimburse them for business-related expenses, including advances exceeding HK$100,000 that were never settled.
The claims suggest ongoing financial strain within the company, though Sanhe Biotech has not publicly responded to the allegations as of the report’s publication. The company, which operates in the life sciences sector, has previously been involved in research and development activities focused on biotech innovations.
Industry observers note that wage disputes and reimbursement issues can signal deeper operational or liquidity challenges, particularly in specialized sectors like biotechnology where cash flow is often tied to funding cycles and project milestones.
The employees’ allegations were made public through local media channels, prompting calls for greater transparency regarding the company’s financial obligations to its workforce. No legal proceedings or official statements from Sanhe Biotech have been confirmed in connection with the claims at this time.
